Palivizumab use in subjects with congenital heart disease: Results from the 2000-2004 Palivizumab Outcomes Registry

被引：29

作者：

Cohen S.A. ^{[1
]}

Zanni R. ^{[2
]}

Cohen A. ^{[3
]}

Harrington M. ^{[4
]}

Vanveldhuisen P. ^{[4
]}

Boron M.L. ^{[5
]}

机构：

[1] Children's Primary Care Medical Group, San Diego, CA

[2] Monmouth Medical Center, Long Branch, NJ

[3] Jazz Pharmaceuticals, Palo Alto, CA

[4] Synagis Outcomes Registry Coordinating Center, EMMES Corporation, Rockville, MD

[5] Medical Affairs, MedImmune, Inc., Gaithersburg, MD

来源：

Pediatric Cardiology | 2008年 / 29卷 / 2期

关键词：

Hospitalization; Prematurity; Respiratory syncytial virus;

D O I：

10.1007/s00246-007-9039-5

中图分类号：

学科分类号：

摘要：

The Palivizumab Outcomes Registry prospectively collected data on 19,548 subjects who received respiratory syncytial virus (RSV) prophylaxis with palivizumab during the 2000-2004 RSV seasons. We evaluated the characteristics of enrolled registry subjects with congenital heart disease (CHD) over the four RSV seasons and examined additional information on these subjects collected in the 2002-2004 seasons. The percentage of registry subjects with CHD increased from 4.8% (102/2116) in the first season to 11.4% (688/6050) in the last season. Across all four seasons, 1500 subjects with CHD were enrolled, 71% of whom had acyanotic CHD. The proportion with cyanotic CHD increased from 19.6% (20/102) in the 2000-2001 season to 37.5% (258/688) in the 2003-2004 season, while the proportion of all CHD in the registry more than doubled during this time. The cumulative RSV hospitalization rate was 1.9% among patients with CHD who received prophylaxis. Among subjects with cyanotic and acyanotic CHD, hospitalization rates were 2.6% and 1.6%, respectively. Prospective data collected in the Palivizumab Outcomes Registry provide the largest published dataset available on infants with CHD receiving palivizumab and show low hospitalization rates and use consistent with prelicensure clinical trial data and revised American Academy of Pediatrics guidelines. © 2007 Springer Science+Business Media, LLC.

引用

页码：382 / 387

页数：5

共 18 条

[1]

Altman C.A., Englund J.A., Demmler G., Et al., Respiratory syncytial virus in patients with congenital heart disease: A contemporary look at epidemiology and success of preoperative screening, Pediatr Cardiol, 21, pp. 433-438, (2000)

[2]

Committee on Infectious Disease and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV, Pediatrics, 102, pp. 1211-1216, (1998)

[3]

Committee on Infectious Disease and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections, Pediatrics, 112, pp. 1442-1446, (2003)

[4]

Pickering L.K., Respiratory syncytial virus, pp. 560-566, (2006)

[5]

Boron M., Case example 23: Using registry data to study patterns of use and outcomes, Registries for Evaluating Patient Outcomes: A User's Guide, (2007)

[6]

Feltes T.F., Cabalka A.K., Meissner H.C., Et al., Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease, J Pediatr, 143, pp. 532-540, (2003)

[7]

Hoffman J.I., Kaplan S., The incidence of congenital heart disease, J Am Coll Cardiol, 39, pp. 1890-1900, (2002)

[8]

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants, Pediatrics, 102, pp. 530-537, (1998)

[9]

Khongphatthanayothin A., Wong P.C., Samara Y., Et al., Impact of respiratory syncytial virus infection on surgery for congenital heart disease: Postoperative course and outcome, Crit Care Med, 27, pp. 1974-1981, (1999)

[10]

Leader S., Kohlhase K., Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000., J Pediatr, 143, (2003)

← 1 2 →